Figure 2. Determination of the diease-free survival (DFS) and overall survival (OS) in the CN-AML patients based on the WT1 expression status and other molecular abnormalities.

(A–B) Comparison of the DFS (A) and OS (B) between the CN-AML patients with normal (WT1 ^ctr) or high (WT1 ^op) WT1 gene expression. The mean DFS and OS of patients with WT1 ^op (n = 29) or WT1 ^ctr (n = 74) were 18.9±2.1 vs. 27.8±1.4 mo (p = .016); and 23.6±2.3 vs. 32.5±1.3 mo (p = .003), respectively. (C–D) Comparison of the DFS (C) and OS (D) among three different risk subgroups that were stratified based on molecular abnormalities, i.e., the favorable risk group included CN-AML patients that are carrying the NPM1 ^mt/no FLT3 ^ITD genotypes; the unfavorable risk group with the FLT3 ^ITD genotypes; and the intermediate group are those patients other than the two other groups, i.e., lack of the NPM1 ^mt/no FLT3 ^ITD and FLT3 ^ITD genotypes [⁸]. The average DFS of the patients with favorable (n = 23), intermediate (n = 62) or unfavorable genotype (n = 18) were 30.0±1.0, 26.6±1.6 and 13.9±3.0 mo, respectively. The average OS of the patients with favorable (n = 23), intermediate (n = 62) or unfavorable genotype (n = 18) were 34.2±0.85, 31.4±1.5 and 19.0±2.5 mo, respectively. (E–J) Possible role of WT1 overexpression in determining the DFS (E, G and I) and OS (F, H, and J) among the favorable (E–F; NPM1 ^mt/no FLT3 ^ITD), the intermediate (G–H) and the unfavorable (I–J; FLT3 ^ITD) molecular and risk subgroups. Note that patients with WT1 ^op in the favorable (n = 4) or unfavorable (n = 8) had inferior DFS and OS than their control WT1 ^ctr groups (favorable, n = 19; unfavorable, n = 10). No significant differences of DFS and OS were observed between normal and high WT1 gene expression in the intermediate group. Abbreviations: WT1 ^ctr, normal WT1 expression; WT1 ^op, WT1 overexpression.